For the quarter ending 2026-03-31, SER had $21,470K increase in cash & cash equivalents over the period. -$4,593K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Common stock issued to consultant for services rendered | - | 120 | 46 | 60 |
| Restricted stock units released to consultant for services rendered | - | 0 | 0 | 29 |
| Change in fair value of warrants | - | - | - | 0 |
| Change in fair value of convertible promissory notes | - | 0 | 0 | 0 |
| Change in fair value of warrants liabilities | - | -3,187 | -1,043 | -33 |
| Net loss | -6,898 | -3,336 | -4,595 | -11,284 |
| Depreciation and amortization | 18 | 24 | 16 | 33 |
| Loss on disposal of property and equipment | - | -91 | - | - |
| Non-cash lease expense | 56 | 32 | 55 | 116 |
| Non-cash interest expense | 125 | 138 | 0 | 0 |
| Amortization of debt issuance costs | 64 | 58 | 0 | 0 |
| Gain on warrants expiration | - | 0 | 724 | - |
| Stock-based compensation | 1,077 | 948 | 999 | 1,846 |
| Loss on sale of subsidiary | - | -166 | - | - |
| Change in fair value of liability classified instruments | -1,134 | - | - | - |
| Grant receivable | - | 0 | 0 | - |
| Loss on extinguishment of financial commitment assets and contingent warrants, net | -1,616 | - | - | - |
| Prepaid expenses and other current assets | 500 | 143 | -766 | -50 |
| Accounts payable | 896 | -811 | 1,045 | 963 |
| Accrued expenses | 162 | 67 | -183 | -115 |
| Other current liabilities | 6 | -168 | -182 | 368 |
| Operating lease liabilities | -56 | -32 | -50 | -105 |
| Net cash used in operating activities | -4,568 | -6,033 | -3,850 | -8,072 |
| Purchase of equipment | 25 | 0 | 13 | 46 |
| Net cash used in investing activities | -25 | 0 | -13 | -46 |
| Proceeds from the issuance of common stock and warrants to juvenescence | - | 0 | - | - |
| Principal repayment on loan facilities to juvenescence | - | 0 | 0 | 0 |
| Drawdown on loan facilities from juvenescence | - | 0 | 0 | 0 |
| Principal repayments on finance lease liabilities | - | 0 | 0 | 0 |
| Proceeds from issuance of series a convertible preferred stock, net | - | 0 | 0 | 4,940 |
| Proceeds from issuance of common stock-At The Market Offering Program | - | 476 | 1,523 | 629 |
| Cash and restricted cash acquired in connection with the merger | - | 0 | 0 | 0 |
| Proceeds from the exercise of post-merger warrants by juvenescence | - | 0 | 0 | 0 |
| Proceeds from the exercise of stock options | 8 | 5 | 8 | 2 |
| Proceeds from issuance of common stock-Juvenescence | 0 | 0 | 0 | 4,916 |
| Proceeds from issuance of common stock-At The Market Sales Agreement | 10,169 | - | - | - |
| Proceeds from 2025 convertible note, net | - | 0 | 4,913 | - |
| Proceeds from issuance of common stock and warrants in connection with private placement, net-Private Placement | 15,880 | - | - | - |
| Net cash provided by financing activities | 26,057 | 481 | 6,444 | 10,487 |
| Effect of foreign currency on cash | 6 | -12 | -2 | - |
| Net increase in cash and cash equivalents | 21,470 | -5,564 | 2,579 | 2,369 |
| At beginning of the period | 3,056 | 8,620 | 3,672 | - |
| At end of the period | 24,526 | 3,056 | 8,620 | - |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)